路线三:维持治疗 REMARC研究探索了60-80岁在诱导治疗后达到CR或PR的DLBCL患者接受来那度胺维持治疗2年的疗效,结果显示2年PFS率较安慰剂组提高(从75.0%提升到 80.0%),但未转化为OS获益,因此对于维持治疗能否转化为OS获益及哪些患者能获益依然不明确,...
塞利尼索作为全球首个全新机制的口服选择性核输出蛋白抑制剂,临床研究显示,其可透过血脑屏障对中枢神经系统淋巴瘤具有抗肿瘤活性1,与靶向免疫治疗药物联用,有助于降低耐药及达到协同抗肿瘤作用。基于其独特的作用机制及丰富良好的临床试验...
ZYNLONTA® (loncastuximab tesirine-lpyl) is a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.
Introduction Following completion of chemotherapy with curative intent for DLBCL, for those in remission (CR), numerous national and international guidelines suggest on-going follow-up primarily to detect relapse of disease. For example, the NCCN guidelines suggest that clinical history, examination and...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend tafasitamab-cxix (MONJUVI) + lenalidomide as an NCCN Category 2A preferred second-line or subsequent treatment option (if not previously used) for certain†patients living with DLBCL.3‡...
诊断时骨髓受累也不常见,仅占20%-30%,NCCN Guidelines for Treatment of Non-Hodgkin Lymphoma. . Accessed May 30, 2012.,诊断,诊断性活检,是初次诊断时,推荐进行切除或切取活检细针穿刺 (FNA) 对细胞类型的鉴别价值有限,但有助于淋巴瘤与其他情况的鉴别 排除混合淋巴瘤提供足够的组织,进行诊断所必需的辅助...
However, due to the lack of clear evidence that stratif i cation of treatment based on these subtypes improves prognosis, the practice is generally not recommended [4–6].This chapter will cover DLBCL, NOS as well as certain DLBCL subtypes (T-cell/histiocyte-rich large B-cell lym-phoma; ...
Polatuzumab vedotin-piiq (POLIVY) +R-CHPis theonly Category 1 recommended treatment optionacross all stages of previously untreated DLBCL for certain* patients2 NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their app...
for whom 1 recommended treatment strategy continues to be an auto-HCT per published guidelines.20 In fact, the efficacy of auto-HCT has been recently confirmed in another CIBMTR analysis showing a 41% 5-year PFS in patients in PET-positive PR receiving an auto-HCT regardless of the timing ...
Guidelines for the diagnosis and treatment of diffuse large B-cell lymphoma in China (2013 edition). Chin J Hematol. 2013;34(9):816–9. Google Scholar Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas...